Wave Life Sciences stock
WVENASDAQWave Life Sciences Ltd., HealthcareISIN US94352A1043
38Score 38 out of 100, Weak
Price and trend
42 / 100
Price history
−53% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 51% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 84% below its 52-week high. Largest decline in 11 years: 98% (September 2018 to May 2022).
Chart figures for advanced users
- SMA 50$3.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.09
- The lowest closing price of the last twelve months.
- Resistance$21.31
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Wave Life Sciences Ltd. belongs to the Biotechnology industry (United States) and, with a market value of $674.52M, is number 228 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $42.73M (down 60.5% year on year) and a loss of $204.38M.
- For fiscal 2026, analysts expect on average revenue of $62.39M (up 46%) and adjusted earnings per share of −$1.10.
Show more
- MEQIRI Score 38 out of 100 (Weak): rank 586 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $430.75M, financial debt $43.27M.Stability 68
Weaknesses
- DilutionShare count up 330% since 2020.Capital allocation 18
- Volatile share priceVolatility 167% a year over the last 12 months.Stability 68
- Loss-makingLoss of $210.53M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 60.5% on the prior year. Revenue turned from negative at the start of the period to positive ($42.73M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating −504%, net −478%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 27 Oct 2026EPS reported −$0.30 (expected −$0.33)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 4.0% since 15 Oct 2026.
- Earnings per share
- −$1.10+4.0%
- Revenue
- $62.39M+23.0%
- Earnings per share
- −$1.30+1.7%
- Revenue
- $38.34M+4.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +13.4%Wave does not mention a changed revenue or earnings forecast, but confirms the timeline for clinical data and funding of operations into the third quarter of 2028.
“We ended the third quarter with $431 million in cash equivalents, and marketable securities, which we expect to be sufficient to fund operations into the third quarter of 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $135,072 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Rawcliffe AdrianSale
12 Aug 2026, Board
- Shares
- 12,700
- Price
- $5.29
- Value
- $67,183
- Wagner Heidi LSale
11 Aug 2026, Board
- Shares
- 7,000
- Price
- $6.01
- Value
- $42,070
- Takanashi KenSale
11 Aug 2026, Board
- Shares
- 3,864
- Price
- $6.01
- Value
- $23,223
Show 1 more
- Tan Aik NaSale
11 Aug 2026, Board
- Shares
- 432
- Price
- $6.01
- Value
- $2,596
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Wave Life Sciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Design TherapeuticsDSGN $689.67M37
- Aclaris TherapeuticsACRS $688.38M39
- Kura OncologyKURA $687.67M28
- Sana BiotechnologySANA $686.16M30
- GeronGERN $657.12M35
- Capricor TherapeuticsCAPR $649.77M32
- Monopar TherapeuticsMNPR $612.75M42
- GenfitGNFT.PA $609.09M44
ETFs that hold Wave Life Sciences
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.40% | 0.50% | €127.06M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.04% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 Jan 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.